Actively Recruiting
A Real World Study of Respiratory Critical Disease
Led by Ming Zhong · Updated on 2025-09-10
500
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute Respiratory Distress Syndrome (ARDS) is a sudden and severe lung injury that leads to acute respiratory failure, affecting around 3 million people worldwide each year and accounting for about 10% of intensive care unit admissions. Because there are no specific drug treatments available, mechanical ventilation is the main method used to support patients. This study aims to identify and analyze factors that predict outcomes for patients with ARDS to help improve their prognosis and reduce poor outcomes. This is an observational study where patients with ARDS or at high risk for ARDS are monitored without any investigational treatment intervention. The study observes various clinical measures daily, including chest CT scans, complete blood counts, arterial blood gases, and records fluid balance and mechanical ventilation data continuously after intubation. The study collects detailed health data to better understand ARDS progression and outcomes. Participants will be closely monitored through daily scans, blood tests, and respiratory assessments after enrollment. The main outcomes being measured are mortality rates at 28 and 60 days after diagnosis of ARDS. Monitoring includes continuous mechanical ventilation data and fluid balance whenever changes occur. The study involves informed consent and follows patients during their critical illness to gather real-world information on respiratory failure outcomes.
CONDITIONS
Brief Title
A Real World Study of Respiratory Critical Disease.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with diseases linked to high ARDS risk such as sepsis, pneumonia, multiple trauma, pulmonary contusion, inhalation injury, or massive blood transfusion
- Patients meeting criteria for a high-risk ARDS population
- Patients or legal representatives who have signed informed consent
You will not qualify if you...
- Under 18 years of age
- HIV infection
- Known immune deficiency disorders like leukemia or common variable immunodeficiency
- History of solid organ or bone marrow transplant
- Receiving treatment with G-CSF or GM-CSF
- Patients who have decided to stop active treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 days from ARDS diagnosis
Participants are observed with daily monitoring including chest CT scans, blood counts, arterial blood gases, fluid balance, and mechanical ventilation parameters.
Daily assessments with continuous monitoring during mechanical ventilation
Trial Site Locations
Total: 1 location
1
Fudan University, Zhong Shan Hospital
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Y
Yuxian Wang, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here